identified that FGFR2 alteration was more frequent in poorly cohesive GC than in non-poorly cohesive GC, suggesting that FGFR2 may be a potential therapeutic target for poorly cohesive GC (Wang et al., 2021). Here, FGFR2 is linked to gastric cancer.